Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs

Miret, Jorge A. and Moreno, Javier and Nieto, avier and Carter, Katharine C. and Mullen, Alexander B. and Ambros, Luis and Rodríguez, Casilda and San Andrés, Manuel Ignacio and González, Fernado (2021) Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs. Experimental Parasitology, 220. 108033. ISSN 0014-4894

[thumbnail of Miret-etal-EP-2021-Antileishmanial-efficacy-and-tolerability-of-combined-treatment-with-non-ionic] Text (Miret-etal-EP-2021-Antileishmanial-efficacy-and-tolerability-of-combined-treatment-with-non-ionic)
Miret_etal_EP_2021_Antileishmanial_efficacy_and_tolerability_of_combined_treatment_with_non_ionic.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 7 November 2021.
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

Download (1MB) | Request a copy from the Strathclyde author

    Abstract

    Infection with Leishmania infantum causes the disease visceral leishmaniasis (VL), which is a serious clinical and veterinary problem. The drugs used to treat canine leishmaniasis (CanL) do not cause complete parasite clearance; they can be toxic, and emerging drug resistance in parasite populations limits their clinical utility. Therefore, in this study we have evaluated the toxicity and efficacy of joint treatment with a 1:1 mixture of sodium stibogluconate-NIV (SSG-NIV, 10 mg Sb v/day) and paromomycin-NIV (PMM-NIV, 10 mg PMM/kg/day), given intravenously daily for seven days from day 270 post-infection, to nine-month-old female beagle dogs (n = 6) experimentally infected with Leishmania infantum. Treatment significantly improved the clinical symptoms of VL infection in all the treated dogs, reduced parasite burdens in lymph nodes and bone marrow, and all symptomatic treated dogs, were asymptomatic at 90 days post-treatment. Treatment was associated with a progressive and significant decrease in specific IgG anti-Leishmania antibodies using parasite soluble antigen (p < 0.01) or rK39 (p < 0.01) as the target antigen. In addition, all dogs were classified as parasite negative based on Leishmania nested PCR and quantitative real time PCR tests and as well as an inability to culture of promastigote parasites from lymph nodes and bone marrow tissue samples taken at day 90 post-treatment. However, treatment did not cure the dogs as parasites were detected at 10 months post-treatment, indicating that a different dosing regimen is required to cause long term cure or prevent relapse.

    ORCID iDs

    Miret, Jorge A., Moreno, Javier, Nieto, avier, Carter, Katharine C., Mullen, Alexander B. ORCID logoORCID: https://orcid.org/0000-0001-7475-5543, Ambros, Luis, Rodríguez, Casilda, San Andrés, Manuel Ignacio and González, Fernado;